Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6850537rdf:typepubmed:Citationlld:pubmed
pubmed-article:6850537lifeskim:mentionsumls-concept:C0009402lld:lifeskim
pubmed-article:6850537lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:6850537lifeskim:mentionsumls-concept:C1704241lld:lifeskim
pubmed-article:6850537lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:6850537pubmed:issue1lld:pubmed
pubmed-article:6850537pubmed:dateCreated1983-7-15lld:pubmed
pubmed-article:6850537pubmed:abstractTextSignificant increments in measurable plasma CEA were effected by 2.5 M MgCl2 elution from putative circulating CEA-anti-CEA complexes in 11 of 15 patients with disseminated colorectal cancer and in five of ten patients with a high probability of having subclinical disease (Dukes'C category). Following 2.5 M MgCl2 elution, IgG from a patient with a high CEA increment effected a higher specific binding to 125I-CEA than a similar IgG eluate from a patient with a negligible increment in measurable CEA. These data suggest that CEA is autoimmunogenic and may result in circulating CEA-anti-CEA complex formation. The clinical implications of such complexes in the diagnosis and monitoring of patients with colorectal cancer remain to be determined.lld:pubmed
pubmed-article:6850537pubmed:languageenglld:pubmed
pubmed-article:6850537pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6850537pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6850537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6850537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6850537pubmed:statusMEDLINElld:pubmed
pubmed-article:6850537pubmed:monthJullld:pubmed
pubmed-article:6850537pubmed:issn0008-543Xlld:pubmed
pubmed-article:6850537pubmed:authorpubmed-author:MavligitG MGMlld:pubmed
pubmed-article:6850537pubmed:authorpubmed-author:StuckeySSlld:pubmed
pubmed-article:6850537pubmed:issnTypePrintlld:pubmed
pubmed-article:6850537pubmed:day1lld:pubmed
pubmed-article:6850537pubmed:volume52lld:pubmed
pubmed-article:6850537pubmed:ownerNLMlld:pubmed
pubmed-article:6850537pubmed:authorsCompleteYlld:pubmed
pubmed-article:6850537pubmed:pagination146-9lld:pubmed
pubmed-article:6850537pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6850537pubmed:meshHeadingpubmed-meshheading:6850537-...lld:pubmed
pubmed-article:6850537pubmed:meshHeadingpubmed-meshheading:6850537-...lld:pubmed
pubmed-article:6850537pubmed:meshHeadingpubmed-meshheading:6850537-...lld:pubmed
pubmed-article:6850537pubmed:meshHeadingpubmed-meshheading:6850537-...lld:pubmed
pubmed-article:6850537pubmed:meshHeadingpubmed-meshheading:6850537-...lld:pubmed
pubmed-article:6850537pubmed:year1983lld:pubmed
pubmed-article:6850537pubmed:articleTitleColorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes.lld:pubmed
pubmed-article:6850537pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6850537lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6850537lld:pubmed